Intellia Therapeutics (NTLA)
(Real Time Quote from BATS)
$19.99 USD
-1.18 (-5.57%)
Updated Apr 25, 2024 12:38 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Intellia Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -481.19 | -474.19 | -267.89 | -134.23 | -99.53 |
Depreciation/Amortization & Depletion | 8.98 | 7.57 | 6.89 | 6.31 | 5.59 |
Net Change from Assets/Liabilities | -52.45 | -53.87 | -22.90 | 57.53 | -20.66 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 130.58 | 187.20 | 58.88 | 20.48 | 11.37 |
Net Cash From Operating Activities | -394.09 | -333.29 | -225.03 | -49.91 | -103.24 |
Property & Equipment | -13.99 | -13.41 | -12.76 | -3.59 | -6.79 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -17.36 | 218.55 | -538.02 | -210.90 | 31.97 |
Other Investing Activities | 0.00 | -44.83 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -31.35 | 160.31 | -550.78 | -214.49 | 25.18 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 130.32 | 582.96 | 736.69 | 371.78 | 76.43 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 130.32 | 582.96 | 736.69 | 371.78 | 76.43 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -295.11 | 409.98 | -39.12 | 107.38 | -1.63 |
Cash at Beginning of Period | 535.46 | 125.49 | 164.61 | 57.23 | 58.86 |
Cash at End of Period | 240.35 | 535.46 | 125.49 | 164.61 | 57.23 |
Diluted Net EPS | -5.42 | -6.16 | -3.78 | -2.40 | -2.11 |
Fiscal Year End for Intellia Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -481.19 | -349.03 | -226.81 | -103.13 |
Depreciation/Amortization & Depletion | NA | 8.98 | 6.51 | 4.22 | 2.05 |
Net Change from Assets/Liabilities | NA | -52.45 | -55.56 | -41.87 | -36.90 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 130.58 | 97.05 | 64.81 | 28.64 |
Net Cash From Operating Activities | NA | -394.09 | -301.03 | -199.65 | -109.33 |
Property & Equipment | NA | -13.99 | -12.47 | -8.13 | -3.83 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -17.36 | -64.82 | -148.65 | -118.42 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -31.35 | -77.29 | -156.79 | -122.25 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 130.32 | 23.84 | 4.74 | 2.22 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 130.32 | 23.84 | 4.74 | 2.22 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -295.11 | -354.48 | -351.70 | -229.36 |
Cash at Beginning of Period | NA | 535.46 | 535.46 | 535.46 | 535.46 |
Cash at End of Period | NA | 240.35 | 180.98 | 183.76 | 306.11 |
Diluted Net EPS | NA | -1.47 | -1.38 | -1.40 | -1.17 |